Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The companies will conduct a Phase 2 study to investigate the safety and efficacy of Novos semaglutide and a fixed-dose combination of Gileads FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and in combination in compensated cirrhosis due to NASH
Any misuse of research-only materials runs counter to Umbrella Labs' stated mission, which is to enhance the quality, transparency, and reproducibility of non-clinical science rather than to facilitate unapproved human exposure
3 December 2018
The proportion of phagocytosing PBMC ( Figure 5A ) increased by 47% in both groups after LPS administration until 3 h pi and then decreased to reach the baseline level at 24 h pi
US$ 26.18
US$ 27.00
US$ 25.46
